TSG is collaborating with government and non-profit biomedical research institutions, such as the US National Institutes of Health (NIH) including its National Institute of Allergy and Infectious Diseases (NIAID), US Army Medical Research Institute of Infectious Diseases (USAMRIID), WHO Collaborating Centre for Research & Training on Viral Zoonoses in Thailand, and Korea Research Institute of Chemical Technology. TSG is also collaborating with various universities worldwide.

At present, TSG’s collaborators are preparing to test TSG’s peptide against the rhabdovirus, hantaviridae, flaviviridae, togaviridae and coronavirus (including COVID-19).

TSG’s drug candidate is well positioned for US FDA Fast-Track designation due to its novelty and solution to unmet needs.